Please login or register to print this page.

The British Journal
of Cardiology

This website is intended for healthcare professionals only

2010, Volume 17, Supplement 2

NEWS
Br J Cardiol 2010;17:s2

Are all angiotensin receptors blockers the same?

This supplement is based on the proceedings of a one-day round-table meeting held on 20th February 2010 to debate whether angiotensin receptor blockers (ARBs) have...

Read More

NEWS
Br J Cardiol 2010;17:s3-s5

Comparative ARB pharmacology

Angiotensin II receptor blockers (ARBs) are a class of pharmaceutical agents that modulate the renin-angiotensin-aldosterone system (RAAS), which is responsible for blood pressure (BP) regulation...

Read More

NEWS
Br J Cardiol 2010;17:s6-s9

ARBs in hypertension

High blood pressure (BP) is one of the leading health risk factors for global mortality, being a higher risk factor than tobacco use, high cholesterol...

Read More

NEWS
Br J Cardiol 2010;17:s10-s12

ARBs in chronic heart failure

Heart failure epidemiology The incidence of heart failure (HF) increases with age and its prevalence is increasing due to an ageing population.1 Although some HF patients...

Read More

NEWS
Br J Cardiol 2010;17:s13-s14

ARBs in renal disease

Diabetic nephropathy is estimated to affect up to 40% of patients with type 2 diabetes. Diabetic nephropathy is characterised by proteinuria, hypertension, progressive decline...

Read More

NEWS
Br J Cardiol 2010;17:s14-s15

Costs and benefits of ARBs in practice

National Health Service (NHS) costs in England grew from about £40 billion in the year 2000 to £100 billion today. That is, they have...

Read More

Close

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

Find out more about our membership benefits

Close

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.

Find out more about our membership benefits